ONCOARENDI THERAPEUTICS
OncoArendi Therapeutics specialized in developing and commercializing of therapeutics for neoplastic and inflammatory diseases.
ONCOARENDI THERAPEUTICS
Industry:
Alternative Medicine Biotechnology Emergency Medicine Medical
Founded:
2012-01-01
Address:
Wysokie Mazowieckie, Podlaskie, Poland
Country:
Poland
Website Url:
http://www.oncoarendi.com
Total Employee:
101+
Status:
Active
Total Funding:
60.6 M PLN
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Apple Mobile Web Clips Icon Apache Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail Facebook Sharer
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Employees Featured
Founder
Stock Details
Investors List
New Europe Ventures, LLC
New Europe Ventures, LLC investment in Series A - OncoArendi Therapeutics
Michał Sołowow
Michał Sołowow investment in Series A - OncoArendi Therapeutics
National Center for Research & Development
National Center for Research & Development investment in Grant - OncoArendi Therapeutics
Medical University of Warsaw
Medical University of Warsaw investment in Grant - OncoArendi Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-27 | OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer |
Official Site Inspections
http://www.oncoarendi.com
- Host name: shared-aky43.rev.nazwa.pl
- IP address: 85.128.156.43
- Location: Poland
- Latitude: 52.2394
- Longitude: 21.0362
- Timezone: Europe/Warsaw
More informations about "OncoArendi Therapeutics"
OncoArendi Therapeutics - Crunchbase Company Profile & Funding
OncoArendi Therapeutics is a biopharmaceutical company devoted to finding, creating, and marketing treatments for inflammatory and cancerous conditions. The Company's business …See details»
OncoArendi Therapeutics Gets Listed - Molecure
OncoArendi Therapeutics S.A., an innovative, clinical stage, biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics for cancer and …See details»
Oncoarendi - Products, Competitors, Financials, Employees, …
Molecure, formerly known as OncoArendi, is an innovative biopharmaceutical company focused on the discovery and development of first-in-class small molecule drugs for the treatment of …See details»
OncoArendi Therapeutics - Craft
Mar 25, 2022 OncoArendi Therapeutics is a biotech company focused on discovery and development of small molecule drug candidates. It studies the therapeutic potential of …See details»
INVESTOR & ANALYST PRESENTATION - Molecure
Nov 4, 2021 Potential milestone from OncoArendi and GLPG collaboration / license agreement In-licensing of one or more programs (1-2 years from IND) in core disease areas Attracting …See details»
OncoArendi Therapeutics has received the final report from
OncoArendi Therapeutics is the first and so far only biotechnology company in the world, which conducts clinical trials of drug candidates targeting chitinase (first-in-class). In April 2020 …See details»
OncoArendi Therapeutics is significantly moving closer to the start …
Feb 8, 2022 OncoArendi has received scientific advice from the European Medicines Agency (EMA) on the clinical development of OATD-02 and has signed an agreement with BIOMAPAS …See details»
OncoArendi Therapeutics supervisory board welcomes …
Jan 14, 2022 OncoArendi is a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and develop first in class small molecule drug candidates …See details»
OncoArendi Therapeutics Reports Continued Strategic and …
Mar 25, 2022 Marcin Szumowski, CEO and President of the Management Board of OncoArendi commented: "We have made excellent progress during 2021 on key strategic initiatives …See details»
Joint MSU/UofM IP acquired by OncoArendi Therapeutics
11 March 2022 – OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal chemistry capabilities to discover …See details»
OncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr.
Jan 31, 2022 OncoArendi's headquarters and laboratories are located in Warsaw, Poland with an additional laboratory in Łódź. The company is listed on the Warsaw Stock Exchange (ticker: …See details»
OncoArendi Therapeutics Reports Continued Strategic and
Mar 25, 2022 OncoArendi has an exclusive collaboration and license agreement with Galapagos for the global development and commercialization of OncoArendi’s OATD-01. OATD-01 …See details»
OncoArendi Therapeutics - Molecure
OncoArendi Therapeutics Good dealmaker OncoArendi’s share price has risen 131% in the last 12M fueled by signing of a partnering agreement with Galapagos in the OATD-01/GLPG4716 …See details»
OncoArendi Therapeutics Reports Continued Strategic and …
Mar 25, 2022 OncoArendi has an exclusive collaboration and license agreement with Galapagos for the global development and commercialization of OncoArendi’s OATD-01. OATD-01 …See details»
Galapagos, OncoArendi team up to develop fibrosis therapy
Nov 6, 2020 Galapagos NV and OncoArendi Therapeutics SA entered into a collaboration and license deal to develop OncoArendi's OATD-01 for treating idiopathic pulmonary fibrosis. …See details»
OncoArendi Therapeutics to Begin the Phase 1 ... - World Pharma …
OncoArendi Therapeutics announced today that this week the Company will initiate a Phase 1 study designed to assess the safety, tolerability and pharmacokinetics of its lead compound, …See details»
OncoArendi Therapeutics Announces a License Option ... - Molecure
11 March 2022 – OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal chemistry capabilities to discover …See details»
OncoArendi Therapeutics Announces a License Option Agreement …
Mar 11, 2022 Adam Golebiowski, VP Research Chemistry and co-founder of OncoArendi added, "We are confident that we can use our medicinal chemistry engine to unlock the potential of …See details»
Organization and comprehensive execution of the phase I
E-mail: [email protected] phone no. +48 573 900 610 Kinga Kazimierczak e-mail: [email protected] Anna Bajera e-mail: [email protected] phone no. …See details»